Search

Search Constraints

You searched for: Author/Creator Weigel, Brenda

Search Results

1. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A children's oncology group phase 1 consortium study. Issue 9 (28th March 2013)

2. A phase I trial of MK‐2206 in children with refractory malignancies: A Children's Oncology Group study. Issue 7 (24th March 2014)

3. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. (March 2020)

4. ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development?. Issue 11 (November 2022)

5. ACCELERATE – Five years accelerating cancer drug development for children and adolescents. (May 2022)

6. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti‐angiogenic therapy: A report from the children's oncology group phase I consortium. Issue 1 (24th September 2014)

7. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. (December 2022)

8. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration2. (January 2022)

9. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. (September 2022)

10. Patterns of chemotherapy‐induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Issue 9 (23rd March 2017)